Syneos Health, Inc. (NASDAQ:SYNH) Shares Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP increased its position in shares of Syneos Health, Inc. (NASDAQ:SYNHGet Rating) by 1.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,171,275 shares of the company’s stock after acquiring an additional 11,869 shares during the quarter. Artemis Investment Management LLP owned approximately 1.14% of Syneos Health worth $94,711,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Syneos Health by 7.7% during the fourth quarter. BlackRock Inc. now owns 9,910,450 shares of the company’s stock worth $1,017,605,000 after acquiring an additional 707,665 shares during the last quarter. State Street Corp boosted its position in Syneos Health by 3.3% during the fourth quarter. State Street Corp now owns 2,599,069 shares of the company’s stock worth $266,872,000 after acquiring an additional 82,093 shares during the last quarter. GW&K Investment Management LLC boosted its position in Syneos Health by 2.0% during the fourth quarter. GW&K Investment Management LLC now owns 1,611,918 shares of the company’s stock worth $165,511,000 after acquiring an additional 31,598 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its position in Syneos Health by 490.6% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,427,767 shares of the company’s stock worth $145,924,000 after acquiring an additional 1,186,001 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Syneos Health by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,364,937 shares of the company’s stock worth $140,151,000 after acquiring an additional 14,724 shares during the last quarter. Hedge funds and other institutional investors own 98.38% of the company’s stock.

A number of equities analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Syneos Health in a report on Monday, May 23rd. They issued a “buy” rating and a $81.00 price target on the stock. Mizuho reiterated a “buy” rating and issued a $94.00 price target on shares of Syneos Health in a report on Friday, May 20th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Syneos Health in a report on Monday, April 11th. They issued a “buy” rating and a $102.00 price target on the stock. Jefferies Financial Group lowered shares of Syneos Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $101.00 to $75.00 in a report on Monday, April 25th. Finally, TheStreet lowered shares of Syneos Health from a “b” rating to a “c+” rating in a report on Wednesday, May 18th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Syneos Health currently has a consensus rating of “Moderate Buy” and an average target price of $98.78.

Shares of SYNH stock opened at $71.57 on Friday. The company’s fifty day simple moving average is $70.52 and its 200-day simple moving average is $80.71. Syneos Health, Inc. has a 52 week low of $62.28 and a 52 week high of $104.18. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.89. The company has a market cap of $7.34 billion, a PE ratio of 30.98 and a beta of 1.78.

Syneos Health (NASDAQ:SYNHGet Rating) last released its quarterly earnings results on Friday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.05. Syneos Health had a net margin of 4.54% and a return on equity of 13.33%. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the firm posted $0.66 EPS. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. Equities research analysts expect that Syneos Health, Inc. will post 4.64 EPS for the current fiscal year.

Syneos Health Profile (Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Featured Articles

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNHGet Rating).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.